Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants - Chuaypen, Natthaya; Siripongsakun, Surachate; Hiranrat, Pantajaree; Tanpowpong, Natthaporn; Avihingsanon, Anchalee; Tangkijvanich, Pisit (PloS one, 2022)
Keywords: Acyltransferase; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; Biology and Life Sciences; Biopsy; Body mass; Body mass index; Body size; Care and treatment; Development and progression; Diabetes; Diabetes mellitus; Eradication; Fatty liver; Fatty Liver - diagnostic imaging; Fatty Liver - drug therapy; Fatty Liver - genetics; Fibrosis; Genetic diversity; Genetic factors; Genetic variance; Genotype; Genotypes; Hepacivirus - genetics; Hepatitis C; Hepatitis C - drug therapy; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - genetics; HIV; Human immunodeficiency virus; Humans; Infections; Lipase - genetics; Lipase - therapeutic use; Liver; Liver Cirrhosis - complications; Liver Cirrhosis - diagnostic imaging; Liver Cirrhosis - genetics; Magnetic resonance; Magnetic resonance imaging; Medicine and Health Sciences; Membrane Proteins - genetics; Multivariate analysis; Patients; Physical Sciences; Polymorphism, Single Nucleotide; Proton density (concentration); Protons; Research and Analysis Methods; Steatosis; Viruses; Thailand; United States--US; Bangkok Thailand